Relmada Therapeutics, Inc. RLMD Share-Based Payment - Unrecognized Cost of Nonvested Awards
Share-Based Payment - Unrecognized Cost of Nonvested Awards at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue.
The official record: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Relmada Therapeutics, Inc.'s share-based payment - unrecognized cost of nonvested awards.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Relmada Therapeutics, Inc.'s share-based payment - unrecognized cost of nonvested awards?
- Relmada Therapeutics, Inc. (RLMD) reported share-based payment - unrecognized cost of nonvested awards of $2.10 in Q1 2026.
- What is the long-term trend for Relmada Therapeutics, Inc.'s share-based payment - unrecognized cost of nonvested awards?
- Over 3 years (2020 to 2025), Relmada Therapeutics, Inc.'s share-based payment - unrecognized cost of nonvested awards has grown at a -99.6% compound annual growth rate (CAGR), from $53,502,000.00 to $2.86.
- What does share-based payment - unrecognized cost of nonvested awards mean?
- This represents the total compensation expense for equity-based awards that has been granted but not yet recognized in the income statement because the vesting conditions have not been met. It serves as a forward-looking indicator of future non-cash compensation expenses. Investors use this to forecast the impact of stock-based compensation on future earnings.